Citadel Advisors’s Alpha Tau Medical DRTS Stock Holding History

Citadel Advisors’s Portfolio DRTS Stock Details DRTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$250K	Buy	+35,395	New	+$250K	﹤0.01%	10906
2025 Q4	–	Sell	-60,600	Closed	-$255K	–	12917
2025 Q3	$273K	Sell	60,600 -5,879	-9%	-$20K	﹤0.01%	10580
2025 Q2	$207K	Buy	66,479 +6,631	+11%	+$18.7K	﹤0.01%	10602
2025 Q1	$150K	Buy	+59,848	New	+$188K	﹤0.01%	10870
2024 Q4	–	Sell	-16,301	Closed	-$38.8K	–	14689
2024 Q3	$38.8K	Buy	+16,301	New	+$36.1K	﹤0.01%	12173
2022 Q2	–	Sell	-15,668	Closed	-$185K	–	13094
2022 Q1	$185K	Buy	+15,668	New	+$184K	﹤0.01%	11626

Other funds holding DRTS

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Aquamarine Financial George Town $1.37B AUM

Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Kovitz Investment Group Partners Chicago, Illinois $4.31B AUM 20.41% 1-Year Est. Return

DSC

Daytona Street Capital Saint Louis, Missouri $130M AUM

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $102M AUM

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

Citadel Advisors's DRTS Position: Q1 2026 in Review

Citadel Advisors opened a new position in Alpha Tau Medical (DRTS) in Q1 2026: 35,395 shares worth $250K. The stake represents ﹤0.01% of the portfolio and ranks #10906 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in DRTS as recently as Q3 2025.

Citadel Advisors first reported a position in DRTS in Q1 2022 and has held it in 6 quarters since. The position peaked at $273K in Q3 2025. 53 funds tracked by Wall St. Rank hold DRTS as of Q1 2026.

Citadel Advisors held 35,395 shares of Alpha Tau Medical worth $250K as of Q1 2026.
Alpha Tau Medical was a new Citadel Advisors position in Q1 2026.
Alpha Tau Medical made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10906 holding.
Citadel Advisors first reported a position in Alpha Tau Medical in Q1 2022 and has held it in 6 quarters since.
Citadel Advisors's Alpha Tau Medical position peaked at $273K in Q3 2025.
53 funds tracked by Wall St. Rank held Alpha Tau Medical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.